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S296 Poster Session Iwhere the next most common toxicities. Solitary cases of cardiotox-
icity, renal dysfunction, and orthostatic hypotension were observed.
Conclusion: Based on this small cohort of relapsed, transplant
eligible MM patients, DPACE appears to be safe and effective
salvage therapy that may serve as a bridge to ASCT. Ongoing
work is being performed to compare the effectiveness of this reg-
imen with other salvage therapies used in a similar population of
MM patients and to measure progression free and overall survival
after treatment.248
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Background: About 1/3 of advanced Hodgkin lymphoma (HL) pa-
tients fail first line therapy and are candidates for autologous stem
cell transplantation (ASCT). Surveillance, Epidemiology and End
Results (SEER) data indicates a bi-modal age distribution and supe-
rior survival among children/adolescents with HL (Bazzeh 2010).
The aim of this study was to analyze the impact of age on overall sur-
vival (OS) among patients with relapsed/refractory HL undergoing
ASCT. We hypothesized that 1) HL patients undergoing ASCT
have a bi-modal age distribution; 2) the older age cohort has inferior
OS after ASCT.
Patients andMethods:We performed an IRB approved, retrospec-
tive analysis of a combined cohort of 131 adult and pediatric HL pa-
tients undergoing ASCT at Emory University from 1995 to 2011.
The cohort included 54% male, 65% Caucasians, and 26% African
American patients. OS was compared using Kaplan Meier estimates
for the time-to-event analysis and log rank test. Univariate and mul-
tivariate Cox proportional hazards models were used to test our hy-
potheses.
Results: Hypothesis 1: Two age cohorts of HSCT patients were
identified: younger (#35 years, n 5 96) and older (.35 years old,
n5 35), based on a bimodal distribution similar to SEER incidence.
Hypothesis 2: Univariate analysis showed a significantly higher post-
transplant mortality (p5 0.004) for patients.35 compared to those
#35 years. Multivariate analysis, adjusting for gender, race, histol-
ogy, disease status at transplant and stage, showed a hazard ratio of
2.4 for patients.35 years compared to those#35 years of age. His-
tology was similar across the age groups, with 75% patients having
nodular sclerosing histology.
Conclusions:Our analysis showsmarkedly inferiorOS among older
patients with undergoing ASCT.The age related differences in post-
transplant survival were not explained by the decreased actuarial life
expectancy of older subjects based upon life-table projections of sur-
vival for the general population.While there were differences in sup-
portive care, toxicity from treatments, and co-morbid diseases
among older HL patients undergoing ASCT compared with youn-
ger HL patients, the inferior survival of older HL patients undergo-
ing ASCT suggests that theremay be differences in the biology of the
disease based upon the age at which HL is diagnosed. Alternative
strategies for autologous transplantation of older patients with re-
lapsed/refractory HL are needed.249
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Houston, TX; 2Cross Cancer Institute, Edmonton, AB, CanadaLymphomas are heterogeneous diseases that require combination
therapy for an effective control. A sizable fraction of patients still fail
to respond, or suffer progressive disease, after initially responding to
treatment. In this setting, hematopoietic stem cell transplantation
(HSCT) has been effective particularly in patients who respond to
salvage chemotherapy. In an attempt to design more efficacious
and safe pre-HSCT conditioning treatment, we expanded our
previous observation on the synergistic cytotoxicity of nucleoside-
analog-(NA) andDNA alkylating agent (AA) and investigated the in-
teractions between AAs busulfan (Bu) and melphalan (Mel) and NA
gemcitabine (Gem) in human lymphoma cell line J45.01. We used
IC10 drug concentrations (57 mM Bu, 1 mM Mel and 0.02 mM
Gem) which individually did not have significant effects on cell pro-
liferation. However, their combination resulted in 50% inhibition of
proliferation. Reduction to almost half (20 mM Bu, 0.7 mMMel and
0.01 mM Gem) did not result in inhibition of cell proliferation. Ad-
dition of 0.6 mM suberoylanilide hydroxamic acid (SAHA) to the lat-
ter combination resulted in 65% inhibition of proliferation. The
synergistic cytotoxicity of [Bu+Mel+Gem+SAHA] combinations
correlates with the activation of the ATM-CHK2 pathway, phos-
phorylaton of KAP1, epigenetic changes such as methylation and
acetylation of histone 3, and activation of apoptosis. We deduce
that chromatin alterations mediated by Gem and SAHA may make
genomic DNAmore accessible to DNA alkylation by Bu andMel re-
sulting in increased DNA lesions and commitment of cells to apo-
ptosis. The relevance of epigenetic changes in this drug exposure is
further shown by the induction of expression of DNA methyltrans-
ferases in lymphoma (and leukemia) cells, which have low constitu-
tive levels of DNMT3A and DNMT3B proteins. The addition of
5-aza-2’-deoxycytidine (DAC) to [Bu+Mel+Gem+SAHA] further
enhances cell killing.Our results suggest that epigenetic changesme-
diated by Gem, SAHA and DAC alter chromatin structure and en-
hance DNA alkylation with Bu and Mel. Such effects are further
aggravated by the ability of Gem to inhibit ribonucleotide reductase
andDNA repair. In summary, this study expands our previous obser-
vation of NA-mediated synergistic toxicity mediated by AAs, and
provides a basis to justify future mechanism-based clinical trials us-
ing [Bu+Mel+Gem+SAHA] as pre-HSCT conditioning for patients
with chemotherapy-refractory lymphoma.250
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African Americans (AA) have twice the risk of developing mul-
tiple myeloma (MM) and, in prior studies, a higher mortality rate
when compared to non-African Americans (non-AA). Novel
agents, such as thalidomide, lenalidomide and bortezomib have
improved the outcome of MM patients but the impact of these
new therapies in AA patients has not been evaluated. In this
study, 53 consecutive patients (23 AA, 30 non-AA) with newly di-
agnosed MM were retrospectively analyzed after induction treat-
ment incorporating a novel agent. AA and non-AA patients were
comparable for age, immunoglobulin isotype, stage of disease, se-
rum albumin level, and cytogenetic abnormalities including del13
(27% vs. 38%, respectively, p 5 NS). Median serum level of a^2
microglobulin at diagnosis was higher in AA than non-AA (5.9
mg/L vs. 3.5 mg/L, p 5 0.024). Using the international uniform
criteria, response rates to induction therapy were not statistically
different between AA and non-AA: overall response rate (ORR,
91% vs. 77%), complete remission (CR, 22% vs. 27%), very
good partial remission (VGPR, 26% vs. 20%), or partial remis-
sion (PR, 43% vs. 30%). However, rate of progressive disease
was significantly higher in non-AA patients (p 5 0.03). Of 53 pa-
tients, 46 (20 AA, 26 non-AA) received standard high-dose che-
motherapy followed by autologous stem cell transplant (ASCT).
With a median follow-up of 47 months, the ORR to ASCT
was 89% in AA and 85% in non-AA, CR+VGPR rates were
61% in AA and 45% in non-AA (p 5 NS). Disease-free survival
